Pharma brand planning, positioning, and lifecycle

Pharmaceutical Market Segmentation: Bases, Methods, and Pitfalls

How pharmaceutical market segmentation works: bases for HCPs, patients, and payers, common methods, how to validate segments, and how to use them.

Christian Guerrero Published 3 min read Part 4 of 10

The short answer

Pharmaceutical market segmentation divides a market into groups that need different strategies. Brands segment HCPs by specialty, volume, behavior, and attitude; patients by condition severity, treatment history, and needs; and payers or organizations by coverage and influence. Good segments are large enough to matter, different enough to need a different approach, and reachable with available data.

Segmentation is easy to start and hard to use. Most brands have a segmentation deck. Fewer have segments that change which HCPs get which message in which channel. This article focuses on segmentation that drives action.

Three markets to segment

Pharma has three customer groups, each with its own segmentation:

Market Common bases Typical data
HCPs Specialty, setting, volume, behavior, attitude, access NPI, claims, surveys, CRM
Patients Severity, line of therapy, comorbidities, needs, demographics Claims, EHR, research
Payers and organizations Coverage, influence, size Formulary data, affiliation data

The article on target marketing in pharma covers how segmentation leads into targeting and positioning. Here we focus on methods.

Segmentation methods

Rule-based

Groups defined by clear rules, such as specialty plus a volume threshold. Easy to explain and apply. Limited depth.

Behavioral

Groups based on prescribing patterns: early adopter, loyal to competitor, broad prescriber. Built from claims. The HCP segmentation models article compares behavioral and attitudinal approaches.

Attitudinal

Groups based on beliefs and needs from surveys, such as "evidence-driven" or "patient-experience focused." Rich insight, but you only know the segment for surveyed HCPs unless you build a model to project it.

Statistical clustering

Algorithms group HCPs or patients by many variables at once. Can find patterns humans miss. Results can be unstable and hard to explain.

Most useful segmentations combine a simple rule-based frame with behavioral or attitudinal layers.

Testing whether segments are useful

Good segments pass five checks:

  1. Measurable. You can tell which segment an HCP or patient is in.
  2. Substantial. The segment is large enough or valuable enough.
  3. Different. Segments respond differently to messages or channels.
  4. Reachable. You can target the segment with available data and media.
  5. Stable. Membership does not flip every month.

The fourth check is where many segmentations fail. Attitudinal segments from a survey of 400 HCPs cannot be targeted across 20,000 HCPs unless you model them, and that model has error.

Using segments in media

  • Build each segment as an NPI list or an audience definition.
  • Assign messages and channel weight by segment.
  • Report reach and outcomes by segment.
  • Keep a holdout within key segments to measure effect.

Common mistakes

  • Too many segments to act on.
  • Segments that cannot be found in targetable data.
  • Never refreshing segment membership.
  • Treating a clustering output as fact without checking stability.

Practical takeaway

For each segment in your current deck, ask: can a media partner target it today, and would it get a different message or channel weight? If both answers are no, merge it into another segment.

Frequently asked questions

What are the bases of segmentation in pharma?

Demographic and professional (specialty, setting), behavioral (prescribing volume and patterns), attitudinal (beliefs and needs), and for patients, clinical (severity, line of therapy) and needs-based factors.

What is the difference between segmentation and targeting?

Segmentation divides the market into groups. Targeting chooses which groups to prioritize and how much to invest in each.

How many segments should a brand use?

Usually few enough that each gets a distinct strategy, often three to six. More segments than you can act on add complexity without value.

Sources

External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.

Working through this decision on a real plan?

I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.